These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8211970)

  • 21. Trientine-induced neurological deterioration in a patient with Wilson's disease.
    Kim B; Chung SJ; Shin HW
    J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A study of trientine therapy in Wilson's disease with neurological symptoms].
    Suda M; Kubota J; Yamaguchi Y; Fujioka Y; Saito Y; Aoki T
    No To Hattatsu; 1993 Sep; 25(5):429-34. PubMed ID: 8398232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mechanism of excretion of trientine from the rat kidney: trientine is not recognized by the H+/organic cation transporter.
    Kobayashi M; Tanabe R; Sugawara M; Iseki K; Miyazaki K
    J Pharm Pharmacol; 1997 Apr; 49(4):426-9. PubMed ID: 9232542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The urinary excretion of radiocopper in presymptomatic and symptomatic Wilson's disease, heterozygotes and controls: its significance in diagnosis and management.
    Gibbs K; Hanka R; Walshe JM
    Q J Med; 1978 Jul; 47(187):349-64. PubMed ID: 715173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of cholecystokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson's disease.
    Iyengar V; Brewer GJ; Dick RD; Chung OY
    J Lab Clin Med; 1988 Mar; 111(3):267-74. PubMed ID: 3125292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults.
    Cho HY; Blum RA; Sunderland T; Cooper GJ; Jusko WJ
    J Clin Pharmacol; 2009 Aug; 49(8):916-28. PubMed ID: 19602718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of triethylenetetramine (TETA) and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry (LC-MS).
    Lu J; Chan YK; Poppitt SD; Cooper GJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(1):62-8. PubMed ID: 17901001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New possibilities in the treatment of Wilson-Konovalov disease (hepatolenticular degeneration)].
    Kolarski V
    Vutr Boles; 1987; 26(5):37-40. PubMed ID: 3433729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wilson's disease: current status.
    Yarze JC; Martin P; Muñoz SJ; Friedman LS
    Am J Med; 1992 Jun; 92(6):643-54. PubMed ID: 1605146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
    Hyvönen MT; Weisell J; Khomutov AR; Alhonen L; Vepsäläinen J; Keinänen TA
    Drug Metab Dispos; 2013 Jan; 41(1):30-2. PubMed ID: 23024204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.
    Askari FK; Greenson J; Dick RD; Johnson VD; Brewer GJ
    J Lab Clin Med; 2003 Dec; 142(6):385-90. PubMed ID: 14713890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abnormalities of copper metabolism in Wilson's disease and their relationship to the aminoaciduria.
    BEARN AG; KUNKEL HG
    J Clin Invest; 1954 Mar; 33(3):400-9. PubMed ID: 13143088
    [No Abstract]   [Full Text] [Related]  

  • 35. [Control of the therapeutic prevention of copper uptake in the liver in Wilson's disease following oral administration of 64Cu].
    Günther K; Siegemund R; Lössner J; Kühn HJ
    Radiobiol Radiother (Berl); 1988; 29(2):226-9. PubMed ID: 3399664
    [No Abstract]   [Full Text] [Related]  

  • 36. Chelating polymeric beads as potential therapeutics for Wilson's disease.
    Mattová J; Poučková P; Kučka J; Skodová M; Vetrík M; Stěpánek P; Urbánek P; Petřík M; Nový Z; Hrubý M
    Eur J Pharm Sci; 2014 Oct; 62():1-7. PubMed ID: 24815561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two male patients with Wilson's disease treated using trientine and iron reduction therapy.
    Hayashi H; Ueno T; Yano M; Okada T; Mabuchi H
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1627-8. PubMed ID: 16174091
    [No Abstract]   [Full Text] [Related]  

  • 38. Active uptake of hydrophilic copper complex Cu(ii)-TETA in primary cultures of neonatal rat cardiomyocytes.
    Fu C; Lizhao J; Luo Z; Wang T; Grapperhaus CA; Ding X; Kang YJ
    Metallomics; 2019 Mar; 11(3):565-575. PubMed ID: 30761393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Wilson's disease: physiopathology, therapeutic approach and case report].
    Gallo V; Riva P; Sidoli L; Bisbocci D
    Minerva Gastroenterol Dietol; 1994 Dec; 40(4):197-201. PubMed ID: 7849148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride.
    Sone K; Maeda M; Wakabayashi K; Takeichi N; Mori M; Sugimura T; Nagao M
    Hepatology; 1996 Apr; 23(4):764-70. PubMed ID: 8666330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.